CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study
DOI 10.1055/a-1234-5891
Bibliografische Angaben
Nachweis in CareLit
Autor:innenMilka Marinova, Reza Alamdar, Hojjat Ahmadzadehfar, Markus Essler, Ulrike Attenberger, Martin Mücke, Rupert Conrad
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe06/2020
Jahrgang / SeitenJg. 59 · S. 409-414
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Introduction To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response. Methods Thirty patients (age range 50–87 years, median…
Zitieren
Zitierempfehlung
Milka Marinova, Reza Alamdar, Hojjat Ahmadzadehfar, Markus Essler, Ulrike Attenberger, Martin Mücke, Rupert Conrad (2020) Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. Nuklearmedizin - NuclearMedicine, 59 (06), 409-414. https://doi.org/10.1055/a-1234-5891
Mit CareLit weiterarbeiten